The University of Mississippi Medical Center recognizes that many of the therapeutic advances in the treatment of cancer and related diseases is a result of collaborative efforts. This institution can best utilize its resources and offer patients the opportunity to receive superior treatment by utilizing its capabilities cooperatively through full participation in the Southwest Oncology Group. To extend participation in the Group and expand our collaborative efforts, we are active participants in the Cooperative Group Outreach Program (CGOP) and plan to participate in forthcoming cancer control research and prevention studies. Patients studied are adults with hematologic malignancies or solid tumors with blacks representing approximately 53% of the cancer cases at the University of Mississippi Medical Center. A multidisciplinary approach to the management of patients is employed by a team of medical oncologists, hematologists, radiation oncologists,, surgeons and surgical subspecialties, geneticists, and immunologists and pathologists. Data managers and nurse oncologists are actively involved in identifying patients for participation and monitoring patients placed on studies. The primary objective in this institution's participation in the Southwest Oncology Group is the collaborative development of studies which will ultimately increase the cure rate of patients with cancer and related diseases and the provision of these treatment programs to all who can benefit from them. A by-product of this research is improved education for students, housestaff and primary physicians as well as a synergetic meshing of ideas for the management of cancer and related diseases. Institutional investigators actively participate in disease, discipline, standing and administrative committees of the Group. Groupwide leadership is demonstrated by this institution's chairing of the Data Managers Committee, participation in disease committee working groups, and the Board of Governors. The institution continues to serve as the depot pharmacy for a major intergroup study conducted for prostate cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA016385-19
Application #
3556363
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-01-01
Project End
1997-12-31
Budget Start
1993-02-15
Budget End
1993-12-31
Support Year
19
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Mississippi Medical Center
Department
Type
Schools of Medicine
DUNS #
928824473
City
Jackson
State
MS
Country
United States
Zip Code
39216
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
El-Khoueiry, A B; Rankin, C; Siegel, A B et al. (2014) S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 110:882-7

Showing the most recent 10 out of 124 publications